{
    "clinical_study": {
        "@rank": "168293", 
        "acronym": "FIT", 
        "arm_group": [
            {
                "arm_group_label": "Fostamatinib Disodium", 
                "arm_group_type": "Active Comparator", 
                "description": "Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet PO bid (morning and evening) over the course of 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether fostamatinib is safe and effective  in the\n      treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP)."
        }, 
        "brief_title": "A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenic Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of persistent/chronic ITP for at least 3 months.\n\n          -  Average platelet count < 30,000/\u00b5L (and none > 35,000 unless as a result of rescue\n             therapy) from at least 3 qualifying counts\n\n        Exclusion Criteria:\n\n          -  Clinical diagnosis of autoimmune hemolytic anemia\n\n          -  Uncontrolled or poorly controlled hypertension\n\n          -  History of coagulopathy including prothrombotic conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076399", 
            "org_study_id": "C-935788-047", 
            "secondary_id": "2013-005452-15"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fostamatinib Disodium", 
                "description": "Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.", 
                "intervention_name": "Fostamatinib Disodium", 
                "intervention_type": "Drug", 
                "other_name": [
                    "R935788", 
                    "R788", 
                    "Fostamatinib"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablet PO bid (morning and evening) over the course of 24 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Persistent Immune Thrombocytopenic Purpura", 
            "Chronic Immune Thrombocytopenic Purpura"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Adam Boruchov, MD", 
                    "phone": "860-714-4680"
                }, 
                "facility": {
                    "address": {
                        "city": "Hartford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06105"
                    }, 
                    "name": "Saint Francis Medical Group Inc"
                }, 
                "investigator": {
                    "last_name": "Adam Boruchov, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ralph Boccia, MD", 
                    "phone": "240-482-0526"
                }, 
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Center for Cancer and Blood Disorders"
                }, 
                "investigator": {
                    "last_name": "Ralph Boccia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura", 
        "overall_contact": {
            "email": "alowe@rigel.com", 
            "last_name": "Ann Lowe, MD", 
            "phone": "512-502-5353"
        }, 
        "overall_official": {
            "affiliation": "Rigel Pharmaceuticals, Inc.", 
            "last_name": "Ann Lowe, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Denmark: Danish Health and Medicines Authority", 
                "Hungary: National Institute of Pharmacy", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Italy: The Italian Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Stable platelet response by Week 24 defined as a platelet count of at least 50,000/\u00b5L on at least 4 of the 6 visits between Weeks 14-24.", 
            "measure": "Stable platelet response of at least 50,000/\u00b5L", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076399"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rigel Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rigel Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}